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SUMMARY
Background There is little information on the efficacy and side effects of antidepressant treatment in elderly patients with
combined depression and cognitive impairment without dementia (DEP-MCI), and it is unclear if cognitive performance
improves with antidepressant response in these patients.
Methods In 39 elderly DEP-MCI patients, changes in depression and cognitive impairment were evaluated with open
sertraline treatment up to 200 mg/day for 12 weeks.
Results Of the 26 completers, 17 were responders and nine were non-responders. Diagnostic subtype of depression was
unrelated to response. ANCOVA on WAIS-R digit symbol percent change scores revealed a significant effect for responder
status (F¼ 5.59, p< 0.03), and age (F¼ 0.24, p< 0.64) and education (F¼ 1.64, p< 0.22) were not significant covariates.
From pre-trial to post-trial, responders improved in WAIS-R digit symbol percent change scores (Mean10% SD 24) while
non-responders declined (Mean 14% SD 18; t¼ 2.60, p< 0.02). Other neuropsychological measures were unrelated to
response. Percent change in HRSD scores showed significant inverse correlations with percent change in several cognitive
measures.
Conclusions DEP-MCI patients showed moderate clinical response to sertraline treatment. When responders were com-
pared to non-responders, cognitive improvement was limited to one measure of attention and executive function. Overall,
there was little cognitive improvement with antidepressant treatment. The findings indirectly suggest that lack of improve-
ment in cognition following treatment of depression in DEP-MCI patients may be associated with increased risk of meeting
diagnostic criteria for dementia during follow-up. Copyright # 2003 John Wiley & Sons, Ltd.
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The most common late-life neuropsychiatric disorders
are depression and dementia, with both identified as
major public health problems that will grow rapidly
with the aging population in the 21st century
(Alexopoulos et al., 1993a; Devanand et al., 1996).
Epidemiological studies report a 10 to 35% prevalence
of depressive symptoms in the elderly (Blazer et al.,
1987; Devanand et al., 1996; Bassuk et al., 1998),
and a 10 to 40% prevalence of cognitive impairment
that increases markedly with age (Coria et al., 1993;
Hanninen et al., 1995; Koivisto et al., 1995). As the
elderly population increases, the proportion of patients
with concurrent depression (DEP) and mild cognitive
impairment (MCI; Peterson et al., 1995), defined
broadly in this paper to include subjects between ‘nor-
mal’ and ‘dementia’, will also increase. Depressive
and cognitive disorders frequently co-exist in elderly
patients (Boone et al., 1992; Kindermann and Brown,
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1997) and the association between DEP and MCI, or
DEP and dementia, may go beyond chance (Burt et al.,
1995; Henderson et al., 1997). Clinical (Alexopoulos
et al., 1993a) and epidemiologic (Devanand et al.,
1996; Bassuk et al., 1998) studies suggest that the pre-
sence of depression (DEP) increases the risk of
dementia in patients with mild cognitive deficits, with
few dissenting reports (Chen et al., 1999).
Neuropsychological test profiles typically differ
between patients with depression and mild dementia.
Patients with early dementia, primarily Alzheimer’s
disease (AD), have delayed word recall test deficits
(Coen et al., 1997), verbal learning task deficits (Delis
et al., 1992), and language deficits (Hill et al., 1992).
In contrast, the memory impairments in depression
seem to be secondary to deficits in attention and moti-
vation (Weingartner et al., 1983). Most studies in
patients with MDD (Burt et al., 1995), including ger-
iatric MDD (Kindermann and Brown, 1997), have
reported a robust and consistent decrease in task per-
formance in the areas of speed of information proces-
sing, motor functioning, and executive function
(Boone, 1995; Kindermann and Brown, 1997).
Attention, psychomotor and executive function
deficits can be severely impaired during depression,
and are likely to reverse with remission of depression
(La Rue et al., 1986; Reynolds et al., 1987). In con-
trast, memory deficits are mild to moderate in severity
and typically are believed not to reverse with remis-
sion of depression (Cohen et al., 1982; Sternberg
and Jarvik, 1986). Clinical trials using tricyclic anti-
depressants (TCAs) or electroconvulsive therapy
(ECT) in elderly patients with major depression
(MDD) suggest that cognitive deficits often improve
along with recovery from depression (Reynolds
et al., 1987; Sackeim et al., 1993). However, in
DEP-MCI patients, it is not known which cognitive
deficits reverse after effective antidepressant treat-
ment, or whether patients who have persistent cogni-
tive deficits after treatment are likely to develop
dementia. The clinical bias has been to treat the
depression first and if cognitive impairment persists,
then complete a neuropsychiatric work-up for demen-
tia (Rabins et al., 1984; Emery and Oxman, 1992).
These clinical views have not been tested systemati-
cally in treatment trials in DEP-MCI patients.
We conducted an open 12-week trial of antidepres-
sant treatment with sertraline, with neuropsychologi-
cal testing conducted before and after the trial. The
hypotheses were that performance on tests of atten-
tion and executive function would improve to a
greater extent in responders compared to non-
responders to sertraline treatment, but changes in
memory and language performance would not be
associated with treatment response.
SUBJECTS AND METHODS
Outpatients 50 years of age or older were recruited
from two sources at the New York State Psychiatric
Institute: Memory Disorders Clinic (54% of patients)
and Late Life Depression Clinic (46% of patients).
These clinics specialize in conducting clinical research
studies in outpatients with cognitive impairment/
dementia and geriatric depression, respectively. The
Memory Disorders Clinic recruited patients primarily
through physician referral and the Life Depression
Clinic recruited patients primarily through advertising.
The study protocol was approved by the Institu-
tional Review Board of the New York State Psychia-
tric Institute. All patients provided written informed
consent.
Inclusion/exclusion criteria
All patients met inclusion criteria for depression and
cognitive impairment without dementia. Inclusion
criteria for depression were the presence of depressed
mood or lack of interest for2 consecutive weeks and
a 17-item Hamilton Rating Scale for Depression
(HRSD) 8. Patients who met DSM-IV criteria for
major depressive disorder, dysthymic disorder, or
depression NOS (not otherwise specified) were
included. Exclusion criteria were the presence of
any contraindication to sertraline, lack of response
in the current depressive episode to a minimum
six-week trial of an SSRI at an adequate dose (fluox-
etine 40 mg/day, sertraline 150 mg/day, paroxe-
tine 40 mg/day, or citalopram 40 mg/day), active
suicidal ideation or plan, psychotherapy (any type)
at a frequency greater than once/month, diagnosis of
dementia, stroke (clinically manifest), major neurolo-
gical disorders, alcohol or substance abuse or depen-
dence in the past six months, bipolar disorder,
schizophrenia or other psychotic disorder, and severe
unstable medical conditions.
Inclusion criteria for cognitive impairment were
the presence of intellectual impairment for 6
months and 10 years, and impaired neuropsycholo-
gical test performance (>1 SD below standardized
norms) on at least one test from a brief neuropsycho-
logical battery: WAIS-R digit span, digit symbol and
similarities subtests, 15-item subtest of the Boston
Naming test, animal naming and CFL (verbal flu-
ency), Selective Reminding Test (SRT; delayed
recall), and two cancellation tasks (letter and shape;
time to complete these tasks). Exclusion criteria were
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a Mini-Mental State Examination (MMSE; Folstein
et al., 1975) score <17 out of 30 or a clinical diagno-
sis of dementia based on a consensus conference.
At initial evaluation, the study psychiatrist obtained
a detailed medical history and conducted a general
physical, neurological, and psychiatric examination.
Electrocardiogram, and blood work including complete
blood count, electrolytes, liver and renal functions, and
thyroid functions were completed prior to study entry.
Brain CT or MRI scan was done when indicated.
Depression evaluations
A research social worker administered the SCID-P at
baseline to evaluate Axis I disorders. The study psy-
chiatrist administered the 17-item Hamilton Rating
Scale for Depression (HRSD) and the Clinical Global
Impression (CGI) at each study visit. On the HRSD,
inter–rater reliability was established in 20 patients
between the raters with an intraclass correlation coef-
ficient of 0.95. The patient completed the Beck
Depression Inventory II self-report at each visit. The
study psychiatrist (D.P.D. or G.H.P.) conducted clini-
cal management based on standard therapeutic princi-
ples in antidepressant clinical trials, and completed
side effect ratings using the Treatment Emergent
Symptom Scale (TESS) that was modified for SSRI
side effects by adding items for sexual dysfunction
and restlessness/jitteriness.
Cognition evaluations
A trained technician administered the brief neuropsy-
chological test battery at the start and end of the trial.
These tests were chosen because they tap into areas
(attention, memory, language, abstract reasoning,
executive function) that are known to be affected in
MCI and in depressive disorders.
Other measures
Age of onset of depressive illness (current and first-
ever episode), and age of onset of cognitive impair-
ment, were determined by evaluation of all medical
records, interviewing the patient, and interviewing
an informant when available (Alexopoulos et al.,
1993b). The modified Blessed Functional Activity
Scale (Parts I and II) was used to assess activities of
daily life (Blessed et al., 1968; Stern et al., 1990).
Treatment trial
The minimum pre-study washout for psychotropic
medications was seven days. Putative antidepressants
such as St John’s wort also required a seven-day
washout. Other medications not known to interact
adversely with sertraline were not changed during
the study. During the trial, lorazepam equivalents up
to 2 mg/day were permitted to treat anxiety/insomnia.
In this 12-week trial, patients were evaluated at
one-week intervals for the first two weeks and subse-
quently at two-week intervals. Patients started sertra-
line (A.M. dose) at 50 mg/day for the first week. In the
absence of intolerable side effects, the dose was raised
to 100 mg/day. At the end of week 4, if the patient did
not meet criteria for response in the absence of intol-
erable side effects, the dose was raised to 150 mg/day
for the next four weeks, and to 200 mg/day for the final
four weeks in the absence of clinical response or
intolerable side effects. At any time-point in the trial,
if the patient met response criteria that dose was con-
tinued for the rest of the trial unless subsequent loss of
clinical response or incident side effects required
further change in dosage.
Both the following criteria needed to be met for
antidepressant treatment response: CGI (assessing
depression only) score of 1 (not at all ill) or 2 (border-
line mentally ill) on the study psychiatrist’s evalua-
tion, and 50% decline in HRSD scores from
baseline.
At eight weeks into the treatment trial, blood levels
for sertraline and desmethyl sertraline levels were
drawn 12–24 hours post-oral dose.
Statistical analyses
In descriptive statistics, the results for continuous
variables are expressed as mean (SD), and as percen-
tages for categorical variables. All statistical tests
were two-tailed.
For patients who exited the protocol before com-
pletion, repeat neuropsychological testing was not
completed at the point of exit. Therefore, intent-to-
treat analyses with the last observation carried for-
ward could not be conducted in this trial, and the main
analyses were completer analyses. ANCOVAs were
conducted separately on the percent change in each
of the neuropsychological measures from pre- to
post-trial, with responder status as the between sub-
ject factor and age and education as covariates. Fol-
lowing the ANCOVAs, post hoc t-tests were used to
evaluate differences between responders and non-
responders. Pearson correlation coefficients were
used to evaluate the associations between percent
change in HRSD scores and the neuropsychological
measures. Student’s t-test was used to compare
responders and non-responders on the percent change
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in TESS scores. The criterion for significance was
alpha¼ 0.05.
RESULTS
The demographic and clinical features of the 39
patients are described in Table 1. The ethnic distribu-
tion was 66.7% non-Hispanic white, 28.2% Hispanic
and 5.1% African–American. Memory complaints
were the first symptom in 46.2% of patients, depres-
sion was the first symptom in 35.9% of patients, and
the chronological sequence of these two symptoms
was unclear in 17.9% of patients. Memory decline
was reported as more disturbing by 28.2%, depression
as more disturbing by 48.7%, and both as equally dis-
turbing by 23.1%. In the index episode, 56.4% of
patients had not received any treatment for depres-
sion, 38.5% had received antidepressant medication,
2.6% had received psychotherapy, and 2.6% had
received combined medication and psychotherapy.
Most patients (84.6%) were not taking putative cogni-
tive enhancers; 2.6% were taking cholinesterase inhi-
bitors, 5.1% were taking vitamin E, 5.1% were taking
ginkgo biloba and 5.1% were taking more than one
such medication. These putative cognitive enhancers
were kept constant in dosage throughout the treatment
trial.
Efficacy and cognitive change
Twenty-six of the 39 study participants completed the
trial. Reasons for early protocol exit were acute gas-
trointestinal distress (n¼ 3), anorgasmia (n¼ 1),
other somatic side effects (n¼ 2), increase in anxiety
(n¼ 2), withdrawal of consent (n¼ 1), moving resi-
dence (n¼ 1), and other reasons (n¼ 3).
Of the 26 completers, 17 were responders and nine
were non-responders. Response was unrelated to sub-
type of depression (major depression n¼ 13 vs rest of
sample n¼ 13; 2¼ 0.2, p< 0.7) and percent change
in Blessed Functional Activity Scores (t¼ 0.7,
p< 0.5). Responders were younger (Mean 66.8 years,
SD 9.4) than non-responders (Mean 82.3 years, SD
5.0; t¼ 4.6, p< 0.001). Age showed a significant
inverse correlation with baseline scores on SRT
delayed recall (r¼  0.40, p< 0.05), but not with
the other neuropsychological measures. Age of onset
of depressive symptoms and age of onset of cognitive
impairment were unrelated to treatment response. The
type of first symptom (depression or cognitive impair-
ment) and the more subjectively distressing symptom
(depression or cognitive impairment) were unrelated
to treatment response (2¼ 4.3, p< 0.12 and
2¼ 2.0, p< 0.4, respectively). Sex was unrelated
to responder status and to all neuropsychological test
scores (baseline, or percent change from pre-trial to
post-trial). Education in years was unrelated to
response (t¼ 0.6, p< 0.6), but showed significant cor-
relations with baseline scores on WAIS-R similarities
(r¼ 0.63, p< 0.001), WAIS-R digit symbol (r¼ 0.57,
p< 0.05), and verbal fluency (CFL r¼ 0.40, p< 0.05;
animal naming r¼ 0.45, p< 0.03), but not with the
other neuropsychological measures. Based on these
associations, only age and education were included
as covariates in the analyses.
Separate ANCOVAs were conducted on the percent
change in each of the neuropsychological measures
from pre- to post-trial, with responder status as the
between-subject factor and age and education as cov-
ariates (Table 2). In these analyses, responder effects
were observed only on WAIS-R digit symbol scores.
ANCOVA on percent change in WAIS-R digit symbol
scores revealed a significant effect for response
(F3,23¼ 5.59, p< 0.03), and age (F3,23¼ 0.24,
p< 0.64) and education (F3,23¼ 1.64, p< 0.22) were
not significant covariates. Responders improved in
WAIS-R digit symbol percent change scores (Mean
10% SD 24) while non-responders declined (Mean
14% SD 18; t¼ 2.60, p< 0.02). Among the 17
responders, seven showed >10% improvement, three
showed >10% decline and seven did not change
(improve or decline by more than 10%) in WAIS-R
digit symbol scores. Among the nine non-responders,
none showed >10% improvement, five showed
>10% decline and four did not change (improve or
Table 1. Demographic and clinical features of 39 patients with
depression and cognitive impairment
Baseline features Mean (SD) or %
Age in years 72.0 (10.2)
Sex (% female) 64.1%
Education in years 12.0 (4.8)
Duration of memory complaints in months 33.5 (24.4)
Duration of depressive complaints in months 24.4 (20.6)
Family history of depression 22%
Family history of dementia 36.5%
Self-referred (includes brought in by informant) 73.7%
Age first depressed in years 63.9 (16.6)
Current major depression 53.8%
History of major depression 33.3%
17-item HRSD 15.4 (4.5)
Folstein MMSE score 25.7 (3.8)
CGI illness severity (range 1 to 7) 3.4 (0.5)
CIRS-G (number of medical illnesses) 3.7 (2.2)
MMSE¼Mini-Mental State Examination range 0–30; CGI¼Cli-
nical Global Impression; CIRS-G¼Cumulative Illness Rating
Scale-Geriatric.
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decline by more than 10%) in WAIS-R digit symbol
scores (Table 3).
Percent change in HRSD scores showed a trend-
level inverse correlation with percent change in
MMS (r¼  0.38, p< 0.06), and significant inverse
correlations with percent change in SRT total recall
(r¼  0.44, p< 0.03), percent change in WAIS-R
digit symbol (r¼  0.53, p< 0.01), and percent
change in time to complete a letter cancellation task
(r¼  0.51, p< 0.01), but not with the other neurop-
sychological measures.
Somatic side effects
Responders reported significantly less side effects
than non-responders in percent change in total TESS
scores (responders Mean 30% SD 30 vs non-respon-
ders Mean 10%, SD 30, t¼ 3.3, p< 0.005).
Oral dose and blood levels
The mean end-point sertraline oral dose did not differ
between responders (Mean 144.1 SD 52.7 mg/day)
and non-responders (Mean 147.2 SD 40.4 mg/day;
t¼ 0.15, p< 0.9). Sertraline blood levels tended to
be higher in responders (Mean 84.8 ng/ml SD 59.5)
compared to non-responders (Mean 43.8 ng/ml SD
23.4; t¼ 1.96, p< 0.07), and desmethyl sertraline
levels tended to be higher in responders (Mean
108.5 ng/ml SD 48.7) compared to non-responders
(Mean 72.6 ng/ml SD 35.8; t¼ 1.98, p< 0.07).
Table 2. ANCOVAs on neuropsychological measures (% change
scores) with response (17 responders, nine non-responders) as
between subject factor, and age and education as covariates
Dependent variable Between subject, F p<
covariates
Folstein MMSE Responder 0.65 0.43
Age 4.73 0.05
Education 0.10 0.76
Digit span Responder 0.06 0.80
Age 0.43 0.52
Education 3.82 0.07
SRT total recall Responder 0.0 0.99
Age 2.15 0.16
Education 1.42 0.25
SRT delayed recall Responder 1.01 0.33
Age 0.01 0.92
Education 0.03 0.86
Verbal fluency CFL Responder 0.46 0.51
Age 0.72 0.41
Education 0.38 0.55
Animal naming Responder 1.71 0.21
Age 0.60 0.45
Education 3.41 0.08
Boston naming Responder 2.37 0.14
Age 0.01 0.92
Education 0.51 0.48
WAIS-R similarities Responder 0.07 0.80
Age 0.68 0.42
Education 1.06 0.31
WAIS-R digit symbol Responder 5.59 0.03
Age 0.24 0.64
Education 1.64 0.22
Letter cancellation time Responder 0.41 0.54
Age 2.13 0.55
Education 1.26 0.28
Shape cancellation time Responder 1.60 0.22
Age 4.73 0.05
Education 0.40 0.54
Table 3. Neuropsychological test scores in responders (n¼ 17) and non-responders (n¼ 9) pre-trial and end-trial
Neuropsychological measure Responders Non-responders
Pre-trial End-trial Pre-trial End-trial
Mean SD Mean SD Mean SD Mean SD
Folstein Mini-Mental State Examination 25.7 3.3 26.4 3.0 25.7 3.8 24.7 3.0
Digit span (forwardþ back) 8.8 1.3 8.5 1.5 9.1 1.4 9.0 1.7
SRT total recall 38.3 11.1 38.4 13.5 35.8 7.6 30.8 6.9
SRT delayed recall 4.4 3.2 4.9 2.8 3.4 2.1 3.7 1.7
Verbal fluency CFL 29.0 14.9 31.3 11.6 34.4 12.5 39.0 14.7
Animal naming 12.8 4.6 14.5 4.1 13.0 3.2 12.6 5.0
Boston naming test: 15-item 13.5 1.5 13.4 2.0 13.4 2.1 14.2 1.6
WAIS-R similarities 13.2 7.7 14.2 6.3 16.4 5.9 15.3 6.5
WAIS-R digit symbol 30.7 12.4 33.2 13.9 28.2 9.5 25.3 11.2
Letter cancellation time 89.7 29.4 85.4 35.4 88.6 27.7 91.6 73.5
Shape cancellation time 68.5 22.7 70.2 30.3 71.2 20.5 78.4 36.6
MMSE¼Mini-Mental State Examination; SRT¼ Selective Reminding Test of Buschke and Fuld; WAIS¼Wechsler Adult Intelligence
Scale.
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DISCUSSION
Patients with DEP-MCI showed moderate antidepres-
sant response to open treatment with sertraline for 12
weeks. These results suggest that sertraline represents
a viable treatment option in DEP-MCI patients, and
are consistent with the literature on antidepressant
treatment of depressed elderly patients with and with-
out cognitive impairment (Sternberg and Jarvik,
1976; Reynolds et al., 1987; Nyth et al., 1992). There
is evidence that sertraline treatment is associated with
a small improvement in cognition in normal elderly
volunteers, but practice effects could not be ruled
out in that report (Furlan et al., 2001).
In this study, responders to sertraline improved
more on the WAIS-R digit symbol subtest than non-
responders. This test primarily assesses attention and
executive function. However, percent change in the
WAIS-R digit span, which is a test of attention, did
not differ between responders and non-responders.
Therefore, the findings with measures of attention in
these DEP-MCI patients are only partly consistent
with prior studies involving successful treatment of
depression (Kindermann and Brown, 1997; Newhouse
et al., 2000). There were no significant differences on
the other neuropsychological measures, including
measures of memory. The lack of association between
treatment response and changes in measures of mem-
ory is consistent with most of the literature on cogni-
tive changes with treatment response in major
depression (Kindermann and Brown, 1997). Percent
change in HRSD scores showed significant inverse
correlations with some neuropsychological measures
of psychomotor speed, executive function, memory,
and global cognitive performance, indicating that
improvement in depression (lower HRSD scores)
was associated with improvement in neuropsychologi-
cal test performance in these areas, as has been
reported in studies of depressed patients (Boone
et al., 1992; Kindermann and Brown, 1997).
Given the short interval of 12 weeks between neu-
ropsychological testing sessions, practice effects
should have led to some improvement in cognitive
performance regardless of antidepressant treatment.
The observed lack of change, or worsening, in cogni-
tive performance in several patients is of concern.
This outcome raises the possibility that DEP-MCI is
a high risk group for further cognitive decline or pro-
gression to dementia and, if so, there is a need to iden-
tify which patients will become demented. Studies in
patients with DEP-MCI or similar disorders suggest
that there is a two-to-five fold increased risk of con-
version to a clinical diagnosis of dementia, primarily
AD, during follow-up (Alexopoulos et al., 1993a;
Devanand et al., 1996; Bassuk et al., 1998).
Although there is a lack of published treatment
trials evaluating changes in cognition with antidepres-
sant treatment in DEP-MCI patients, this issue has
been examined in treatment trials of depression in
AD patients. In a multi-center, double-blind placebo-
controlled trial using moclobemide (a reversible
monoamine oxidase inhibitor) in 511 patients with
DEP and AD, there was a significant reduction in
depression scores in 60% of moclobemide treated
patients and 49% of placebo patients. Global cogni-
tive functioning, as measured by the MMSE, impro-
ved significantly more on moclobemide than placebo
(Roth et al., 1996). In a double-blind, placebo-
controlled trial in 149 patients, citalopram signifi-
cantly reduced depression scores in 45% of patients
compared to 24% for placebo (Nyth et al., 1992).
On the Gottfries-Brane-Steen dementia rating scale
(GBS; Gottfries et al., 1982), cognitive and emotional
functioning improved significantly more on citalo-
pram compared to placebo. In contrast, in a double-
blind placebo-controlled trial of imipramine in AD
patients with major depression, Reifler et al. (1989)
found no change in MMSE in either group. In another
double-blind study of 21 subjects with probable AD
and depression, clomipramine was superior to pla-
cebo, with no significant differences on change in
MMSE (Petracca et al., 1996). Katona et al. (1998)
found comparable antidepressant efficacy for imipra-
mine and paroxetine in patients with depression and
probable AD, but no change in cognition in the two
groups. Overall, these controlled trials showed that
improvement in global cognitive tests was either
absent or small in magnitude in patients with AD
and concurrent depression after effective antidepres-
sant treatment. Our findings in DEP-MCI patients
suggest a similar outcome, in that neurospychological
test scores did not improve in most non-responders,
and even in some responders (Table 3). These findings
raise the possibility that a large proportion of these
patients may decline cognitively to meet diagnostic
criteria for dementia, primarily AD, during follow-up.
The limitations of this study were the small sample
size and lack of availability of neuropsychological
testing at the time-point of dropout. As a result, the
statistical analyses were restricted to completer ana-
lyses. Nonetheless, the findings do provide useful
pointers for the clinician: DEP-MCI patients show
moderate clinical response with sertraline treatment,
and cognitive performance in the domains of attention
and executive function can improve with antidepres-
sant treatment. However, in patients whose cognition
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does not improve with antidepressant treatment of
depression, there may be an increased risk of meeting
criteria for dementia during follow-up. Longitudinal
follow-up studies after systematic treatment of DEP-
MCI patients are needed to address this issue.
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